Literature DB >> 12481819

Inhaled nitric oxide.

William E Hurford1.   

Abstract

Inhaled NO offers a novel therapy for the treatment of pulmonary hypertensive diseases and the symptomatic relief of hypoxemia. The use of iNO reduces the necessity for ECMO in newborns and infants with acute hypoxemic respiratory failure. Proper indications, contraindications, dosing criteria, and implications of the toxic actions of NO must be delineated fully. Randomized clinical trials of patients with carefully defined, specific acute disease states that are characterized by pulmonary hypertension or hypoxemia have not been completed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481819     DOI: 10.1016/s1078-5337(02)00008-4

Source DB:  PubMed          Journal:  Respir Care Clin N Am        ISSN: 1078-5337


  3 in total

1.  Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice.

Authors:  Rien van Haperen; Caroline Cheng; Barend M E Mees; Elza van Deel; Monique de Waard; Luc C A van Damme; Teus van Gent; Thijs van Aken; Rob Krams; Dirk J Duncker; Rini de Crom
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

2.  Role of methemoglobin and carboxyhemoglobin levels in predicting COVID-19 prognosis: an observational study.

Authors:  Begüm Oktem; Fatih Üzer; Fatma Mutlu Kukul Güven; İdris Kırhan; Mehmet Topal
Journal:  Med Gas Res       Date:  2020 Oct-Dec

3.  Inhaled nitric oxide: another weapon in our armamentarium in the battle against acute hypoxic respiratory failure in preterm infants.

Authors:  Shonola S Da-Silva; R Phillip Dellinger
Journal:  Crit Care       Date:  2004-02-10       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.